AC Immune Reports First Quarter 2018 Financial Results and Corporate Update

Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease
Selected Tau small molecules (Tau Morphomers) have entered into IND/CTA^* enabling studies; Phase 1 to commence by the end of 2018
Increased R&D investment and resources across our key programs
Financial position remains strong with CHF 109.7 million in cash, allowing the Company to be fully financed through Q2 2019, excluding potential incoming milestones

Find the full media release below.

You may also be interested in

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudular mails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask you
October 8, 2024

The innovative RFID-based solution for prefilled syringes (PFS) aims to boost efficiency and enhance traceability during the fill-and-finish process and product distribution
October 7, 2024

Alithea Genomics, a leader in large-scale RNA sequencing, received a loan guarantee from Switzerland's Technology Fund, aiding its growth. The fund, part of the Swiss Federal Office for the Environment, supports companies reducing greenhouse gas emissions. Alithea's innovative technologies, such as BRB-seq and DRUG-seq, cut costs, time, and resource use in RNA sequencing, promoting sustainability.
September 24, 2024

Industrial biotechnology promotes more energy-efficient and sustainable manufacturing processes as well as creating opportunities for reducing pollution, reusing waste and creating new products. It underpins a circular economy and a more sustainable chemicals industry which prioritizes protecting scarce natural resources. New bio-based products and processes have far-reaching and disruptive impact

Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.
September 24, 2024

ten23 health, a leading Swiss contract development and manufacturing organization (CDMO), yesterday proudly hosted the Grand Opening of its VIVA2 facility in Visp, Switzerland.
September 24, 2024